Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE vs ABRILADA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine is an amide local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. Epinephrine is a vasoconstrictor that prolongs bupivacaine's effect by reducing vascular absorption.
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.
Local or regional anesthesia for surgical procedures,Dental anesthesia,Obstetric anesthesia (e.g., epidural for labor)
Rheumatoid arthritis,Juvenile idiopathic arthritis,Psoriatic arthritis,Ankylosing spondylitis,Crohn's disease,Ulcerative colitis,Plaque psoriasis,Hidradenitis suppurativa,Uveitis
Maximum dose of bupivacaine: 2 mg/kg (not to exceed 175 mg); with epinephrine: 3 mg/kg (not to exceed 225 mg). Administer via local infiltration, peripheral nerve block, epidural, or caudal block. Dose depends on the anesthetic procedure. Repeated doses may be given at intervals of 3-6 hours. Maximum single dose for epidural: 50 mg initially, then 10-25 mg per segment as needed.
80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.
Terminal elimination half-life of bupivacaine is approximately 2.7 hours (range 1.5–5.5 hours) in adults. In neonates, half-life is prolonged (8–12 hours) due to immature hepatic function. The half-life of epinephrine is very short (~1–2 minutes) due to rapid metabolism.
Terminal elimination half-life approximately 10–14 days in adults, supporting every-other-week dosing; may be shorter in pediatric patients.
Bupivacaine is metabolized primarily in the liver via CYP1A2 and CYP3A4 to pipecoloxylidine. Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Adalimumab is a monoclonal antibody that is metabolized via catabolism into peptides and amino acids. CYP450 enzymes are not involved. No active metabolites.
Bupivacaine is primarily metabolized in the liver via CYP3A4 and is excreted renally as metabolites (approximately 95% in urine) and less than 5% unchanged. Epinephrine is rapidly metabolized by COMT and MAO and excreted renally as metabolites.
Primarily degraded into amino acids and recycled or excreted in urine (less than 1% unchanged); no significant biliary/fecal elimination.
Bupivacaine is highly protein-bound (approximately 95%) primarily to alpha-1-acid glycoprotein (AAG) and albumin. Epinephrine is bound to AAG (30–40%) and albumin (10–20%).
Approximately 95% bound to serum proteins, primarily alpha-1-acid glycoprotein and albumin.
Bupivacaine Vd is 0.5–1.0 L/kg. Higher Vd in neonates (1.5–2.0 L/kg) due to increased body fat and decreased protein binding. Epinephrine Vd is 0.2–0.4 L/kg.
Approximately 4.7–6.0 L/kg, indicating extensive distribution into tissues consistent with a monoclonal antibody.
Bupivacaine: Epidural: 100% (bypasses first-pass). Peripheral nerve block: 100%. Intrathecal: 100%. Oral: <10% due to extensive first-pass metabolism. Epinephrine: Bioavailability is 100% for parenteral routes; oral is negligible due to gastrointestinal and hepatic metabolism.
Subcutaneous: approximately 64% (range 50–80%) absolute bioavailability relative to intravenous administration.
No specific dose adjustment for bupivacaine is recommended for renal impairment. Use with caution in severe renal failure (GFR <15 m L/min) due to potential accumulation of metabolites.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use with caution.
For Child-Pugh A: no adjustment. Child-Pugh B: reduce total dose by 25-50%. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction) and close monitoring.
No formal studies in hepatic impairment. Use with caution in moderate to severe impairment (Child-Pugh B or C) due to limited data.
For children >12 years, same as adult. For children ≤12 years, weight-based dosing: bupivacaine without epinephrine: 0.5-1 mg/kg; with epinephrine: 1-2 mg/kg. Maximum single dose: without epinephrine: 2 mg/kg; with epinephrine: 3 mg/kg. Administer by infiltration or regional block. Not recommended in infants <12 months.
Approved for pediatric plaque psoriasis (≥12 years): 80 mg subcutaneously every other week. For pediatric psoriatic arthritis (≥12 years): 80 mg subcutaneously every other week. For pediatric hidradenitis suppurativa (≥12 years, ≥60 kg): 160 mg on day 1, then 80 mg every other week. Pediatric Crohn's disease (≥6 years, ≥40 kg): 160 mg on day 1, then 80 mg on day 15, then 80 mg every other week; for <40 kg: 80 mg on day 1, then 40 mg on day 15, then 40 mg every other week.
Reduce dose by 25-50% in elderly patients due to increased sensitivity and reduced clearance. Lower concentrations (e.g., 0.25%) may be used. Monitor for cardiotoxic effects. Use minimal effective dose.
No specific dose adjustment required; but monitor for infections in patients ≥65 years due to increased risk.
Risk of cardiac arrest and severe hypotension when used for epidural anesthesia in obstetrics; risk of severe neurologic injury (e.g., cauda equina syndrome) with continuous spinal anesthesia.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. SERIOUS INFECTIONS: Patients treated with adalimumab are at increased risk for serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue adalimumab if a serious infection develops. MALIGNANCY: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab.
Risk of systemic toxicity (CNS and cardiovascular) with accidental intravascular injection; use with caution in patients with hepatic disease, severe hypertension, or cardiovascular disease; avoid in patients with arrhythmias or hypotension.
Serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens,Hepatitis B virus reactivation,Hypersensitivity reactions including anaphylaxis and angioneurotic edema,Neurologic events including new onset or exacerbation of demyelinating disorders,Hematologic events including pancytopenia and aplastic anemia,Congestive heart failure,Lupus-like syndrome,Malignancies including lymphoma, leukemia, and other malignancies
Hypersensitivity to bupivacaine or epinephrine; severe hypotension; cardiogenic shock; use in intravenous regional anesthesia (Bier block) due to risk of toxicity; concomitant use with MAOIs or tricyclic antidepressants due to hypertensive crisis.
Known hypersensitivity to adalimumab or any inactive component of the product,Active serious infections including sepsis, tuberculosis, and opportunistic infections
No significant food interactions. Avoid alcohol consumption until effects of anesthesia have worn off to prevent dizziness or syncope.
No significant food interactions. Grapefruit and other CYP450 modulators do not affect adalimumab. Take without regard to meals.
Bupivacaine with epinephrine is classified as FDA Pregnancy Category C. Animal studies have shown adverse fetal effects at high doses, but no adequate human studies exist. First trimester: Risk cannot be ruled out; use only if clearly needed. Second/third trimester: May cause fetal bradycardia and acidosis if absorbed systemically, especially with paracervical block. Avoid use during delivery due to potential for neonatal depression and reduced uterine blood flow from epinephrine.
Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates exposed in utero. First trimester: Minimal known risk. Second/third trimester: May cross placenta; theoretical risk of immunosuppression.
Bupivacaine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.3-0.5. Epinephrine is poorly excreted and rapidly metabolized. The American Academy of Pediatrics considers bupivacaine compatible with breastfeeding. However, observe infant for signs of local anesthetic toxicity (e.g., irritability, apnea) if used repeatedly.
Excreted in human milk in low concentrations; M/P ratio not well defined. Considered compatible with breastfeeding, but monitor infant for infection risks.
Pregnancy may reduce the required dose of bupivacaine due to increased cardiac output and altered protein binding. Standard dosing adjustments are not defined, but cautious dose reduction (e.g., 20-30%) is recommended for epidural or spinal anesthesia to avoid high plasma levels. Epinephrine concentrations should be kept low to minimize uterine vasoconstriction.
No dose adjustment routinely required; pregnancy may increase clearance, but no established guidelines for dose modification.
Bupivacaine-epinephrine combination provides prolonged local anesthesia with vasoconstriction. Maximum dose: bupivacaine 2 mg/kg (3 mg/kg with epinephrine). Avoid in paracervical block (0.25% bupivacaine with epinephrine) due to risk of fetal bradycardia. Contraindicated in severe hypotension, hypovolemia, or concurrent MAOI use. Do not use in patients with sulfite allergy (bisulfite preservative). Epinephrine concentration is 1:200,000 (5 mcg/m L).
ABRILADA (adalimumab) is a TNF-alpha inhibitor. Monitor for latent TB reactivation with PPD or IGRA before initiation. Injection site reactions are common; rotate sites and apply cold compresses. Avoid live vaccines during therapy. Assess for new-onset or worsening heart failure, demyelinating disorders, and cytopenias. Increased risk of serious infections; screen for HBV, HCV, and fungal infections. Consider temporarily holding therapy for major surgical procedures.
Report any signs of allergic reaction: hives, difficulty breathing, swelling of face/lips/tongue.,Numbness may last several hours; avoid chewing or testing the anesthetized area with hot objects.,If you experience chest pain, palpitations, severe headache, or shortness of breath after injection, seek immediate medical attention.,Do not drive or operate machinery until sensation fully returns.,Tell your doctor if you have high blood pressure, heart disease, thyroid problems, or are taking MAO inhibitors or tricyclic antidepressants.
Inspect injection site for redness, swelling, or itching; apply cold compress if needed.,Report signs of infection: fever, cough, painful urination, or skin wounds.,Avoid live vaccines (e.g., MMR, shingles, nasal flu) during treatment.,Review all current medications, including OTC and herbal supplements.,Notify healthcare provider before any planned surgery.,Use reliable contraception if of childbearing potential; continue 5 months after stopping.,Report new or worsening symptoms: shortness of breath, chest pain, numbness, vision changes.,Store ABRILADA in the refrigerator (36°F-46°F); do not freeze or shake.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"The coadministration of bupivacaine, a sodium channel blocker used for local anesthesia, with diclofenamide, a carbonic anhydrase inhibitor and diuretic, may lead to metabolic acidosis and altered electrolyte balance, thereby increasing the risk of bupivacaine-induced cardiotoxicity and central nervous system (CNS) toxicity. Diclofenamide can cause hypokalemia and hypocalcemia, which potentiate the sodium channel blocking effects of bupivacaine, resulting in arrhythmias, seizures, or other adverse effects. This interaction is clinically significant especially in patients with renal impairment or those on multiple electrolyte-altering medications."
"Oxymorphone, a potent mu-opioid receptor agonist, and bupivacaine, a local anesthetic that blocks sodium channels, both depress the central nervous system (CNS) and respiratory drive. Coadministration may lead to additive CNS and respiratory depression, increasing the risk of severe adverse effects such as hypotension, bradycardia, and respiratory arrest. Clinical outcomes include enhanced sedation, confusion, and possibly fatal respiratory compromise, especially in patients with compromised cardiovascular function or those receiving high doses of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE vs ABRILADA, answered by our medical review team.
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE is a Alpha/Beta Agonist that works by Bupivacaine is an amide local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. Epinephrine is a vasoconstrictor that prolongs bupivacaine's effect by reducing vascular absorption.. ABRILADA is a TNF-Alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE and ABRILADA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE is: Maximum dose of bupivacaine: 2 mg/kg (not to exceed 175 mg); with epinephrine: 3 mg/kg (not to exceed 225 mg). Administer via local infiltration, peripheral nerve block, epidural, or caudal block. Dose depends on the anesthetic procedure. Repeated doses may be given at intervals of 3-6 hours. Maximum single dose for epidural: 50 mg initially, then 10-25 mg per segment as needed.. The standard adult dose of ABRILADA is: 80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE and ABRILADA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE is classified as Category A/B. Bupivacaine with epinephrine is classified as FDA Pregnancy Category C. Animal studies have shown adverse fetal effects at high doses, but no adequate human studies exist. First tr. ABRILADA is classified as Category C. Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates expose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.